Standard BioTools Inc (LAB) concluded trading on Thursday at a closing price of $1.04, with 4.7 million shares of worth about $4.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.84% during that period and on February 27, 2025 the price saw a loss of about -10.68%. Currently the company’s common shares owned by public are about 372.26M shares, out of which, 360.49M shares are available for trading.
Stock saw a price change of -22.59% in past 5 days and over the past one month there was a price change of -36.67%. Year-to-date (YTD), LAB shares are showing a performance of -40.29% which decreased to -56.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.15 but also hit the highest price of $3.04 during that period. The average intraday trading volume for Standard BioTools Inc shares is 1.69 million. The stock is currently trading -23.60% below its 20-day simple moving average (SMA20), while that difference is down -36.60% for SMA50 and it goes to -45.36% lower than SMA200.
Standard BioTools Inc (NASDAQ: LAB) currently have 372.26M outstanding shares and institutions hold larger chunk of about 72.48% of that.
The stock has a current market capitalization of $389.01M and its 3Y-monthly beta is at 1.60. It has posted earnings per share of -$0.55 in the same period. It has Quick Ratio of 5.09 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LAB, volatility over the week remained 10.21% while standing at 7.99% over the month.
Stock’s fiscal year EPS is expected to rise by 65.38% while it is estimated to increase by 50.00% in next year. EPS is likely to grow at an annualized rate of 57.47% for next 5-years, compared to annual growth of 11.58% made by the stock over the past 5-years.
Coverage by TD Cowen stated Standard BioTools Inc (LAB) stock as a Buy in their note to investors on April 16, 2024, suggesting a price target of $3.50 for the stock. On April 04, 2024, Jefferies Initiated their recommendations, while on July 12, 2023, KeyBanc Capital Markets Initiated their ratings for the stock with a price target of $4.
